Is Semaglutide Used for Type 2 Diabetes — and What Does That Mean for Weight Loss?

What the clinical evidence actually says about semaglutide and type 2 diabetes

Semaglutide's diabetes credentials go back well before its weight-loss approval. The SUSTAIN trial programme, published across several phases in journals including the New England Journal of Medicine, showed that semaglutide injections reduced HbA1c significantly in adults with type 2 diabetes and also produced meaningful weight reduction as a secondary finding. That secondary finding is part of why the conversation about semaglutide and weight loss became so prominent. Regulators drew a clear line, though: the diabetes licence and the weight-management licence are separate, cover different doses, and serve different clinical purposes.

Wegovy (semaglutide 2.4 mg weekly) was then studied in its own programme, STEP, explicitly for weight management. Wegovy's weight-management licence rests on that STEP evidence, not on the diabetes trials. NICE's appraisal of semaglutide for weight management (TA875) assessed Wegovy specifically, the NICE committee was not recommending Ozempic for weight loss. The MHRA keeps these distinctions sharp, and so do prescribers.

A question our prescribers hear most weeks is whether someone already on Ozempic for diabetes can simply increase their dose to get the weight-loss benefit. The honest answer is that switching between licensed medicines, adjusting doses, or using a product outside its indication are clinical decisions that depend on your full history, your current HbA1c control, your cardiovascular risk, and the medicines you take alongside it. That conversation belongs with your diabetes care team first.

What Wegovy's licence actually covers when type 2 diabetes is part of the picture

Wegovy holds MHRA authorisation for weight management in adults with a BMI of 30 or above, or a BMI of 27 to 29.9 accompanied by at least one weight-related condition. Type 2 diabetes counts as one of those weight-related conditions, which means adults living with type 2 diabetes may fall within the licensed criteria for Wegovy as a weight-management medicine, not as a diabetes treatment.

NICE's recommendation under TA875 adds further conditions: Wegovy is recommended only within a specialist weight management service, for a maximum of two years, and for people with a BMI of 35 or above (or meeting specialist-referral criteria at 30 to 34.9) alongside at least one weight-related comorbidity. Ethnic-background adjustments to those BMI thresholds apply under UK guidance, typically 2.5 kg/m² lower for certain groups. Our page on Wegovy and type 2 diabetes works through the clinical picture for people in this situation more carefully.

If you are managing type 2 diabetes with insulin or an insulin secretagogue such as a sulphonylurea, there is a specific clinical consideration: adding a GLP-1 medicine can increase the risk of low blood sugar, and your diabetes medicines may need to be reviewed at the same time. This is not a reason to avoid the conversation, it is a reason to have it with a prescriber who can look at your full medication list. You can read more about how Wegovy sits alongside type 2 diabetes management on a dedicated page.

What remains uncertain, and who to speak to

The STEP 2 trial studied semaglutide 2.4 mg specifically in adults with type 2 diabetes and overweight or obesity, and found around 10% average weight reduction, lower than the roughly 15% seen in STEP 1 (people without diabetes), reflecting the known biology that blood-sugar-lowering medicines can affect weight outcomes differently in people with versus without diabetes. Whether that gap matters for your individual goals is a clinical discussion, not something a webpage can settle.

There are also things we do not yet know with certainty for every subgroup: how long weight loss is maintained after stopping, how best to sequence GLP-1 medicines alongside newer diabetes medicines, and what the optimal approach looks like for people whose diabetes is well controlled on existing treatment. The NHS semaglutide medicines page is a reliable first reference for current UK guidance. For anyone with type 2 diabetes, the starting point is a conversation with your GP or diabetes specialist alongside any enquiry about weight management. If you are considering private weight-management treatment, starting a free consultation with our prescribers means a clinician (not a form or an algorithm) reads your full health picture the same day and decides whether treatment is appropriate.

One clear boundary: semaglutide in any form is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. Anyone in those situations should speak to their maternity or diabetes care team before making any changes, and anyone planning travel while on treatment may also find it useful to read our guidance on taking Wegovy on holiday, which covers storage, timing, and what to discuss with your prescriber before you go. Our page on Wegovy and pregnancy covers this in detail.